articleThe Brief A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in its phase 1 trial. Researchers at the University of California said 21 out of 25 patients generated an immune response to cancer cells. A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal cancer is showing promising results, according to a recently published study. "This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer-driving mutations. What's next:Researchers have completed enrolling patients for a larger phase 2 study for the ELI-002 7P vaccine, which will target a broader set of KRAS mutations.